Device Devices

Aperio Gt 450 Dx (US) Scanner

Payments companies reported to CMS as associated with Aperio Gt 450 Dx (US) Scanner. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$20Kassociated payments (2023-2025)
18clinicians with associated payments
1company reporting

By year

2024 $14K
2025 $6,391

Payments reported as associated with Aperio Gt 450 Dx (US) Scanner, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Anatomic Pathology & Clinical Pathology $14K
Anatomic Pathology $3,653
Hematology (Pathology) $790
Pediatric Pathology $765
Cytopathology $765
Blood Banking & Transfusion Medicine $675

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Aperio Gt 450 Dx (US) Scanner

These are the largest totals companies reported as associated with Aperio Gt 450 Dx (US) Scanner. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Toby Cornish Milwaukee, WI Anatomic Pathology & Clinical Pathology $5,658.57
Matthew Hanna Pittsburgh, PA Anatomic Pathology & Clinical Pathology $4,754.00
Sylvia Asa Cleveland, OH Anatomic Pathology $2,870.82
Rajesh Dash Durham, NC Anatomic Pathology & Clinical Pathology $1,000.00
Alan Brown San Antonio, TX Anatomic Pathology & Clinical Pathology $816.00
Jonathan Klein Maryville, TN Hematology (Pathology) $790.00
Dane Olevian Morgantown, WV Anatomic Pathology $765.00
Melina Flanagan Philadelphia, PA Cytopathology $765.00
John Ozolek Pittsburgh, PA Pediatric Pathology $765.00
Peter Perrotta Morgantown, WV Blood Banking & Transfusion Medicine $675.00

Prescribed Aperio Gt 450 Dx (US) Scanner?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.